EMMALEE FUMO: Open Payments
NPI 1649950965 · ALBANY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$384 in 20 payments from 8 companies in 2025. Trend: 2023 $218 · 2024 $519 · 2025 $384
Food & beverage: $384
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 5 | $100 |
| GlaxoSmithKline, LLC. | 4 | $84 |
| Optinose US, Inc. | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $28 |
| GENZYME CORPORATION | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
Products named: NUCALA, DUPIXENT, Andembry, Xhance, Hizentra, VOQUEZNA, TAKHZYRO, NEFFY.
Industry payments across NY — which companies pay providers there.
